Peringatan Keamanan

There is limited information on overdose. Up to 4000 mg, which is approximately seven times the recommended dose of the drug, was administered in clinical trials. There is no known specific antidote for casirivimab overdose so treatment of overdose should involve general supportive measures.L39135

Casirivimab

DB15941

biotech approved experimental

Deskripsi

Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19.L23539 This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19.A224429 These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.A221495

On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only.L23524 In November 2021, the same indication was approved by the EMA.L39130,L39135

Full safety and efficacy data are not yet available, and further evaluation of this investigational therapy will continue.L23539,L23529,L14303

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

372 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Casirivimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Casirivimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Casirivimab.
Estrone Estrone may increase the thrombogenic activities of Casirivimab.
Estradiol Estradiol may increase the thrombogenic activities of Casirivimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Casirivimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Casirivimab.
Mestranol Mestranol may increase the thrombogenic activities of Casirivimab.
Estriol Estriol may increase the thrombogenic activities of Casirivimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Casirivimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Casirivimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Casirivimab.
Tibolone Tibolone may increase the thrombogenic activities of Casirivimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Casirivimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Casirivimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Casirivimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Casirivimab.
Zeranol Zeranol may increase the thrombogenic activities of Casirivimab.
Equol Equol may increase the thrombogenic activities of Casirivimab.
Estetrol Estetrol may increase the thrombogenic activities of Casirivimab.
Promestriene Promestriene may increase the thrombogenic activities of Casirivimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Casirivimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Casirivimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Casirivimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Casirivimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Casirivimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Casirivimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Casirivimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Casirivimab.
Formononetin Formononetin may increase the thrombogenic activities of Casirivimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Casirivimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Casirivimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Casirivimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Casirivimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Casirivimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Casirivimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Casirivimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Casirivimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Casirivimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Casirivimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Casirivimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Casirivimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Casirivimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Casirivimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Casirivimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Casirivimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Casirivimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Casirivimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Casirivimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Casirivimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Casirivimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Casirivimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Casirivimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Casirivimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Casirivimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Casirivimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Casirivimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Casirivimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Casirivimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Casirivimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Casirivimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Casirivimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Casirivimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Casirivimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Casirivimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Casirivimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Casirivimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Casirivimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Casirivimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Casirivimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Casirivimab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Casirivimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Casirivimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Casirivimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Casirivimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Casirivimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Casirivimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Casirivimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Casirivimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Casirivimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Casirivimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Casirivimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Casirivimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Casirivimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Casirivimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Casirivimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Casirivimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Casirivimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Casirivimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Casirivimab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Casirivimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Casirivimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Casirivimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Casirivimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Casirivimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Casirivimab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Casirivimab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Casirivimab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Casirivimab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Casirivimab.

Target Protein

Spike glycoprotein S

Referensi & Sumber

Synthesis reference: Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010-1014. doi:10.1126/science.abd0827
Artikel (PubMed)
  • PMID: 32540901
    Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA: Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15.
  • PMID: 32807860
    Matthews DB: A cocktail of antibodies for COVID-19 therapy. Nat Rev Immunol. 2020 Oct;20(10):591. doi: 10.1038/s41577-020-00431-9.
  • PMID: 32203189
    Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19.

Contoh Produk & Brand

Produk: 13 • International brands: 0
Produk
  • Casirivimab
    Injection, solution, concentrate • 300 mg/2.5mL • Intravenous • US
  • Casirivimab
    Injection, solution, concentrate • 1332 mg/11.1mL • Intravenous • US
  • Casirivimab and Imdevimab
    Solution • - • Intravenous • Canada • Approved
  • Casirivimab and Imdevimab
    Solution • - • Intravenous • Canada • Approved
  • Casirivimab With Imdevimab
    Injection, solution, concentrate; Kit • - • Intravenous • US
  • Casirivimab With Imdevimab
    Injection, solution, concentrate; Kit • - • Intravenous • US
  • Regen-cov
    Injection, solution, concentrate • - • Intravenous • US
  • Regen-cov
    Injection • - • Intravenous • US
Menampilkan 8 dari 13 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul